<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/7A2E29F2-7BB5-49F8-A719-BCDDF0C000FA"><gtr:id>7A2E29F2-7BB5-49F8-A719-BCDDF0C000FA</gtr:id><gtr:name>University of Otago</gtr:name><gtr:address><gtr:line1>PO Box 56</gtr:line1><gtr:line4>Dunedin</gtr:line4><gtr:line5>9016</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>New Zealand</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:department>Cambridge Institute for Medical Research</gtr:department><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7A2E29F2-7BB5-49F8-A719-BCDDF0C000FA"><gtr:id>7A2E29F2-7BB5-49F8-A719-BCDDF0C000FA</gtr:id><gtr:name>University of Otago</gtr:name><gtr:address><gtr:line1>PO Box 56</gtr:line1><gtr:line4>Dunedin</gtr:line4><gtr:line5>9016</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>New Zealand</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/26725C18-DCA9-4CC1-AE48-CC3175761A6E"><gtr:id>26725C18-DCA9-4CC1-AE48-CC3175761A6E</gtr:id><gtr:firstName>George</gtr:firstName><gtr:otherNames>Frank</gtr:otherNames><gtr:surname>Mells</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0800460"><gtr:id>2859726E-0EEC-49C1-9DF7-24AB30AA0D82</gtr:id><gtr:title>The Genetic and Molecular Pathogenesis of Primary Biliary Cirrhosis</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G0800460</gtr:grantReference><gtr:abstractText>Primary biliary cirrhosis (PBC) is a chronic liver disease that affects over 1 in 5000 people in the UK. It usually affects middle-aged or older women. There is no effective treatment and many patients eventually develop cirrhosis and liver failure, for which the only treatment is liver transplantation. The cause of PBC is unknown. However, there is evidence that genetic factors are important. For example, PBC may affect more than one member of the same family. This is called familial PBC. The genes involved in causing PBC have not been clearly identified. We intend to study DNA from families in which several relatives have the disease. We will also study a laboratory mouse which develops a liver disease closely resembling PBC. By doing genetic studies of PBC families and the PBC mouse, we hope to identify genes involved in causing the disease. We will then study DNA from a large number of patients with non-familial (sporadic) PBC, to see whether the same genes are involved in causing sporadic disease. This is important because, if we identify the genes involved in causing PBC, investigators will have a better chance of finding a treatment which works.</gtr:abstractText><gtr:technicalSummary>Primary biliary cirrhosis (PBC) is an autoimmune, chronic liver disease characterized by progressive destruction of the small intra-hepatic bile ducts, eventually leading to cirrhosis. The aetiology of PBC is unknown; it is thought to be multifactorial. Epidemiological and twin studies support the role of genetic factors. However, only weak association with HLA-DR8 has been consistently demonstrated. Family based linkage studies have never been reported.
An animal model for PBC has recently been characterised. The NOD.c3c4 strain is a congenic mouse which develops an autoimmune biliary disease (ABD) closely resembling human PBC. In the NOD 2445 strain, the loci necessary for fully penetrant ABD have been refined to Abd1 on chromosome 4
and Abd2 on chromosome 3. 
We have established a unique collection of families in which multiple kindred have PBC. Whole genome linkage analysis of one PBC family has identified two regions associated with disease, PBC1 and PBC2. PBC1 is syntenic to a region adjacent to Abd1 on mouse chromosome 4 (Pbc1). PBC2 harbours a gene implicated in familial cholestasis, ATP8B1. Sequencing of ATP8B1 has shown that affected kindred are homozygous for a mis-sense variant of uncertain pathogenicity. These findings indicate that further family studies will be valuable to dissect the genetic basis of PBC.
We plan to identify genes which confer susceptibility to PBC by studying multiplex PBC families. This will involve: (1) whole genome linkage analysis using high-density SNP arrays; (2) identification of candidate genes in regions linked to disease, and (3) sequencing of candidate genes to identify potentially pathogenic variants. Where variants are identified, their role in sporadic PBC will be investigated in case-control association studies, using tag SNPs from the same gene. Cases will be obtained from an existing PBC DNA collection, and controls from the Wellcome Trust Case Control Consortium. 
Furthermore, we will undertake congenic mouse studies to investigate Pbc1. The NOD 1556 strain contains a B10-derived chromosome 4 region which includes Pbc1. Starting with the 1556 and 2445 strains, congenic mice will be generated to determine whether Pbc1 modifies the ABD phenotype. Sequence variation between NOD and B-10 Pbc1 will be sought to identify the alleles in Pbc1 which are associated with modified disease. This data will be used to guide case-control association studies of sporadic, human PBC. 
By identifying susceptibility alleles, this study will elucidate the pathogenesis of PBC and provide new targets for therapeutic intervention.</gtr:technicalSummary><gtr:fund><gtr:end>2011-12-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2008-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>222324</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Birmingham</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>UK PBC Consortium</gtr:description><gtr:id>AEDD4778-DFE3-4B1A-9EDC-DE416FFE85E3</gtr:id><gtr:impact>UK GWAS of PBC
UK iCHIP study of PBC
International GWMA of PBC
Development of UK-PBC Risk Score
Platform for clinical trials</gtr:impact><gtr:outcomeId>eVU3zFhMRzC-2</gtr:outcomeId><gtr:partnerContribution>Intellectual and assistance with patient recruitmentIntellectual contribution and assistance with recruitmentIntellectual contribution and patient recruitment</gtr:partnerContribution><gtr:piContribution>We established the consortium, which now consists of 98% of all UK liver treatment centres.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Otago</gtr:collaboratingOrganisation><gtr:country>New Zealand</gtr:country><gtr:department>Department of Medicine</gtr:department><gtr:description>UK PBC Consortium</gtr:description><gtr:id>011A0FCE-EA5F-4391-9D9F-006B3042F897</gtr:id><gtr:impact>UK GWAS of PBC
UK iCHIP study of PBC
International GWMA of PBC
Development of UK-PBC Risk Score
Platform for clinical trials</gtr:impact><gtr:outcomeId>eVU3zFhMRzC-3</gtr:outcomeId><gtr:partnerContribution>Intellectual and assistance with patient recruitmentIntellectual contribution and assistance with recruitmentIntellectual contribution and patient recruitment</gtr:partnerContribution><gtr:piContribution>We established the consortium, which now consists of 98% of all UK liver treatment centres.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Newcastle University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Institute of Cellular Medicine</gtr:department><gtr:description>UK PBC Consortium</gtr:description><gtr:id>CE4D1E34-1190-40FE-A2DD-49512FDA2352</gtr:id><gtr:impact>UK GWAS of PBC
UK iCHIP study of PBC
International GWMA of PBC
Development of UK-PBC Risk Score
Platform for clinical trials</gtr:impact><gtr:outcomeId>eVU3zFhMRzC-1</gtr:outcomeId><gtr:partnerContribution>Intellectual and assistance with patient recruitmentIntellectual contribution and assistance with recruitmentIntellectual contribution and patient recruitment</gtr:partnerContribution><gtr:piContribution>We established the consortium, which now consists of 98% of all UK liver treatment centres.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Meetings of PBC Foundation</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>DB971D14-A50F-4684-B051-664E30668ACB</gtr:id><gtr:impact>Annual conference of PBC Foundation- approximately 150 delegates;
PBC Foundation volunteers conference- approximately 50 delegates
Local liver group meeting- approximately 5 members
Articles for the PBC Foundation magazine- readership of 5000 members
Contribution to PBC Foundation Compendium- readership of 5000

PBC Foundation have made a DVD and have requested additional articles for the quarterly newsletter</gtr:impact><gtr:outcomeId>NYu6D5qf5Ss</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2008,2009,2010,2011,2012</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>4793466</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Stratified Medicine in Primary Biliary Cirrhosis (PBC): Understanding Disease Mechanisms and Targeting Therapies (UK-PBC)</gtr:description><gtr:end>2017-11-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/L001489/1</gtr:fundingRef><gtr:id>7D7F377F-EFED-4996-8C3F-BAFAA97C9DE8</gtr:id><gtr:outcomeId>fqE68J3XrBo</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-12-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs><gtr:researchDatabaseAndModelOutput><gtr:description>Model to predict the individual patient's risk of developing liver failure within 5, 10 or 15 years of initiating treatment.</gtr:description><gtr:id>5FA84CDC-1890-4D12-ABDB-E2060148C972</gtr:id><gtr:impact>The model can be used for risk stratification to prioritize higher risk patients for second-line therapies or de-escalate follow-up of lower risk patients back to primary care.</gtr:impact><gtr:outcomeId>56e14211d19751.02454444</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>UK-PBC Risk Score</gtr:title><gtr:type>Computer model/algorithm</gtr:type><gtr:url>http://www.uk-pbc.com/resources/tools/riskcalculator/</gtr:url><gtr:yearFirstProvided>2015</gtr:yearFirstProvided></gtr:researchDatabaseAndModelOutput><gtr:researchDatabaseAndModelOutput><gtr:description>Research database that contains extensive clinical phenotype data for 5,500 PBC patients participating in the UK-PBC project. Used to inform analysis of multi-omic datasets as part of a deep phenotyping/precision medicine initiative.</gtr:description><gtr:id>82468FAA-E653-4C63-8C4E-B0C1A9FBEDCC</gtr:id><gtr:impact>The database was used to develop the UK-PBC Risk Score. The database is also used to identify patients who are potentially eligible for clinical trials. So far the database has supported recruitment into trials by GSK, Lumena, RitPBC, FFP and Intercept.</gtr:impact><gtr:outcomeId>56e1417149f343.82606548</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>UK-PBC Database</gtr:title><gtr:type>Database/Collection of data</gtr:type><gtr:url>http://www.uk-pbc.com/</gtr:url></gtr:researchDatabaseAndModelOutput></gtr:researchDatabaseAndModelOutputs><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>The UKPBC Bioresource consists of a database containing clinical data on each participant in the UKPBC Research Cohort (N ~4,500), accompanied by a DNA collection containing ~4,500 unique samples</gtr:description><gtr:id>13FCF292-F87D-4D01-A901-F5FDB1B0CB04</gtr:id><gtr:impact>Drug companies have shown considerable interest in utilising the database to identify patients suitable for clinical trials.</gtr:impact><gtr:outcomeId>fZe2313tSDc</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>UKPBC Bioresource</gtr:title><gtr:type>Biological samples</gtr:type><gtr:url>http://www.uk-pbc.com/</gtr:url><gtr:yearFirstProvided>2012</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>4339866E-679F-43F4-8911-E848AAEDF308</gtr:id><gtr:title>Fine mapping and replication of genetic risk loci in primary sclerosing cholangitis.</gtr:title><gtr:parentPublicationTitle>Scandinavian journal of gastroenterology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2c21a26e28a3a10ae5fcab9013261116"><gtr:id>2c21a26e28a3a10ae5fcab9013261116</gtr:id><gtr:otherNames>Srivastava B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0036-5521</gtr:issn><gtr:outcomeId>pm_16759_29_22554193</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>78C62C7D-73F4-4225-A419-4C32C89B4EA7</gtr:id><gtr:title>The impact of liver transplantation on the phenotype of primary biliary cirrhosis patients in the UK-PBC cohort.</gtr:title><gtr:parentPublicationTitle>Journal of hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bef041439a8509eeada0bb3b6f6319a1"><gtr:id>bef041439a8509eeada0bb3b6f6319a1</gtr:id><gtr:otherNames>Pells G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0168-8278</gtr:issn><gtr:outcomeId>pm_16759_29_23466308</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>265E15B3-FA13-47FF-AC72-10F531C5036B</gtr:id><gtr:title>Novel insights into autoimmune liver diseases provided by genome-wide association studies.</gtr:title><gtr:parentPublicationTitle>Journal of autoimmunity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/41e21049ed36ea2a66f7459fa8c75155"><gtr:id>41e21049ed36ea2a66f7459fa8c75155</gtr:id><gtr:otherNames>Mells GF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0896-8411</gtr:issn><gtr:outcomeId>pm_16759_29_23931959</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E7BA250A-CB8B-48F5-B681-F13271CB304C</gtr:id><gtr:title>Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid.</gtr:title><gtr:parentPublicationTitle>Gastroenterology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/11d4b10bef9940042a07f07fab866601"><gtr:id>11d4b10bef9940042a07f07fab866601</gtr:id><gtr:otherNames>Carbone M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0016-5085</gtr:issn><gtr:outcomeId>pm_16759_29_23246637</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>474B5D89-6B1E-433D-8EDA-5DE22A305F7A</gtr:id><gtr:title>Impact of primary biliary cirrhosis on perceived quality of life: the UK-PBC national study.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/41e21049ed36ea2a66f7459fa8c75155"><gtr:id>41e21049ed36ea2a66f7459fa8c75155</gtr:id><gtr:otherNames>Mells GF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>pm_16759_29_23471852</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>25D49868-969B-4072-8971-B23BF987A5FA</gtr:id><gtr:title>A validated clinical tool for the prediction of varices in PBC: the Newcastle Varices in PBC Score.</gtr:title><gtr:parentPublicationTitle>Journal of hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bd470b2edf9dbceead7f4c1dc40949c7"><gtr:id>bd470b2edf9dbceead7f4c1dc40949c7</gtr:id><gtr:otherNames>Patanwala I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0168-8278</gtr:issn><gtr:outcomeId>pm_16759_29_23608623</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BBBE70A2-C1A4-40D2-9F5F-685A89FD7F1D</gtr:id><gtr:title>The UK-PBC risk scores: Derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/11d4b10bef9940042a07f07fab866601"><gtr:id>11d4b10bef9940042a07f07fab866601</gtr:id><gtr:otherNames>Carbone M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>56dea48a6ccee1.98283706</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7995810A-DC2F-4036-866C-26B53643468E</gtr:id><gtr:title>Dense fine-mapping study identifies new susceptibility loci for primary biliary cirrhosis.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4f08243406518279380370a3fd236f37"><gtr:id>4f08243406518279380370a3fd236f37</gtr:id><gtr:otherNames>Liu JZ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn><gtr:outcomeId>pm_16759_29_22961000</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>844344AE-86EE-4D49-B548-A85624921E50</gtr:id><gtr:title>Calcineurin inhibitors and the IL12A locus influence risk of recurrent primary biliary cirrhosis after liver transplantation.</gtr:title><gtr:parentPublicationTitle>American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/11d4b10bef9940042a07f07fab866601"><gtr:id>11d4b10bef9940042a07f07fab866601</gtr:id><gtr:otherNames>Carbone M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1600-6135</gtr:issn><gtr:outcomeId>pm_16759_29_23433321</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A38DEE01-A2B2-4C2E-ADC1-036DB9243323</gtr:id><gtr:title>Genome-wide association study identifies 12 new susceptibility loci for primary biliary cirrhosis.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/41e21049ed36ea2a66f7459fa8c75155"><gtr:id>41e21049ed36ea2a66f7459fa8c75155</gtr:id><gtr:otherNames>Mells GF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn><gtr:outcomeId>Bqj3uDnPhGB</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C9267D9F-4593-4F27-95D4-1EFA4B651FA9</gtr:id><gtr:title>International genome-wide meta-analysis identifies new primary biliary cirrhosis risk loci and targetable pathogenic pathways.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/30f2ddcf341db5f03b7129b8dc29e57a"><gtr:id>30f2ddcf341db5f03b7129b8dc29e57a</gtr:id><gtr:otherNames>Cordell HJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>56dea48a367572.80437719</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FD76FFDE-C61B-4A49-822F-03496815EF0A</gtr:id><gtr:title>Making the most of new genetic risk factors - genetic and epigenetic fine mapping of causal autoimmune disease variants.</gtr:title><gtr:parentPublicationTitle>Clinics and research in hepatology and gastroenterology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/41e21049ed36ea2a66f7459fa8c75155"><gtr:id>41e21049ed36ea2a66f7459fa8c75155</gtr:id><gtr:otherNames>Mells GF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2210-7401</gtr:issn><gtr:outcomeId>56e13f66ab2d30.43804999</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>543611EC-5D01-4CF9-B8CA-B1AD61E247D3</gtr:id><gtr:title>The genetics of primary biliary cirrhosis: the revolution moves on.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0624396d5239dd81c84ef38c5d6c9399"><gtr:id>0624396d5239dd81c84ef38c5d6c9399</gtr:id><gtr:otherNames>Jones DE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>pm_16759_29_21254185</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0800460</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>D81A471F-556F-4570-BF6A-5D197943223C</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Oral and Gastrointestinal</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>